Rhinology & Otology

Biography

Biography: Kathleen Campbell

Abstract

In the future, possibly within 5 or earlier, we may be able to prevent or reduce permanent noise- and drug-induced hearing loss by pharmacologic otoprotective agents. Research suggests these agents may be given before or in some cases even after drug or noise exposure. This presentation will review current research in otoprotective agents for drug- and noise- induced ototoxicity including Dr. Campbell’s own research with D-methionine as an otoprotective agent. This presentation will emphasize oral agents in or approaching FDA approved clinical trials. These agents could change audiologic and otolaryngologic practice. These agents are currently in or approaching clinical trials to prevent cisplatin-induced, aminoglycoside induced and noise induced hearing loss. Dr. Campbell’s own clinical trials with D-methionine, funded by the US Department of Defense and under FDA IND approval, are currently in a Phase 3 clinical trial at Ft. Jackson to prevent noise induced hearing loss and tinnitus at Ft. Jackson. This clinical trial and Dr. Campbell’s research was featured on the front page of the Wall Street Journal in 2015. Further some otoprotective agents for cisplatin induced hearing loss have the potential to reduce other side effects of cancer treatments.